Nanotherapeutic Platforms for Cancer Treatment: From Preclinical Development to Clinical Application

Nanoarchitectonics for Smart Delivery and Drug Targeting

Volumn , Issue , 2016, Pages 813-869

  Egusquiaguirre, S P ^a,b   Pedraz, J L ^a,b   Hernandez R M ^a,b   Igartua, M ^a,b  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

Author keywords

Cancer; Liposomes; Nanotechnology based drug delivery systems; Polymeric micelles and polymer or lipid drug conjugate nanoparticles; Polymeric nanoparticles; Preclinical development

Indexed keywords

CELL DEATH; CELL PROLIFERATION; CHEMOTHERAPY; CLINICAL RESEARCH; CONTROLLED DRUG DELIVERY; DIAGNOSIS; DRUG PRODUCTS; ENZYME INHIBITION; LIPOSOMES; MEDICAL NANOTECHNOLOGY; MICELLES; NANOPARTICLES; PATHOLOGY; TARGETED DRUG DELIVERY; TUMORS;

CANCER; DRUG DELIVERY SYSTEM; DRUG-CONJUGATES; POLYMERIC NANOPARTICLES; PRECLINICAL DEVELOPMENT;

DISEASES;

EID: 85018467000     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-47347-7.00029-X     Document Type: Chapter

References (306)

1. Abe S., Otsuki M. Styrene maleic acid neocarzinostatin treatment for hepatocellular carcinoma. Curr. Med. Chem. Anticancer Agents 2002, 2(6):715-726.
2. Akhtar N.H., Pail O., Saran A., Tyrell L., Tagawa S.T. Prostate-specific membrane antigen-based therapeutics. Adv. Urol. 2012, 2012:973820.
3. Aleku M., Schulz P., Keil O., Santel A., Schaeper U., Dieckhoff B., Janke O., Endruschat J., Durieux B., Röder N., Löffler K., Lange C., Fechtner M., Möpert K., Fisch G., Dames S., Arnold W., Jochims K., Giese K., Wiedenmann B., Scholz A., Kaufmann J. Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression. Cancer Res. 2008, 68(23):9788-9798.
4. Allen T.M., Cullis P.R. Liposomal drug delivery systems: from concept to clinical applications. Adv. Drug Deliv. Rev. 2013, 65(1):36-48.
5. Ambasta R.K., Sharma A., Kumar P. Nanoparticle mediated targeting of VEGFR and cancer stem cells for cancer therapy. Vasc. Cell 2011, 3:26.
6. Awada A., Garcia A.A., Chan S., Jerusalem G.H., Coleman R.E., Huizing M.T., Mehdi A., O'Reilly S.M., Hamm J.T., Barrett-Lee P.J., Cocquyt V., Sideras K., Young D.E., Zhao C., Chia Y.L., Hoch U., Hannah A.L., Perez E.A. Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study. Lancet.Oncol. 2013, 14(12):1216-1225. NKTR-102 Study Group.
7. Awada A., Bondarenko I.N., Bonneterre J., Nowara E., Ferrero J.M., Bakshi A.V., Wilke C., Piccart M. A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC). Ann. Oncol. 2014, 25(4):824-831. CT4002 Study Group.
8. Bae K.H., Chung H.J., Park T.G. Nanomaterials for cancer therapy and imaging. Mol. Cell. 2011, 31(4):295-302.
9. Bae K.H., Lee K., Kim C., Park T.G. Surface functionalized hollow manganese oxide nanoparticles for cancer targeted siRNA delivery and magnetic resonance imaging. Biomaterials 2011, 32(1):176-184.
10. Bao W., Liu R., Wang Y., Wang F., Xia G., Zhang H., Li X., Yin H., Chen B. PLGA-PLL-PEG-Tf-based targeted nanoparticles drug delivery system enhance antitumor efficacy via intrinsic apoptosis pathway. Int. J. Nanomed. 2015, 10:557-566.
11. Barenholz, Y., 2012. Doxil®-the first FDA-approved nano-drug: lessons learned. J. Control. Release, 160 2, 117-134.
12. Barraud L., Merle P., Soma E., Lefrançois L., Guerret S., Chevallier M., Dubernet C., Couvreur P., Trépo C., Vitvitski L. Increase of doxorubicin sensitivity by doxorubicin-loading into nanoparticles for hepatocellular carcinoma cells in vitro and in vivo. J. Hepatol. 2005, 42(5):736-743.
13. Batist G., Ramakrishnan G., Rao C.S., Chandrasekharan A., Gutheil J., Guthrie T., Shah P., Khojasteh A., Nair M.K., Hoelzer K., Tkaczuk K., Park Y.C., Lee L.W. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J. Clin. Oncol. 2001, 19(5):1444-1454.
14. Batist G., Gelmon K.A., Chi K.N., Miller W.H., Chia S.K., Mayer L.D., Swenson C.E., Janoff A.S., Louie A.C. Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors. Clin. Cancer Res. 2009, 15(2):692-700.
15. Bedikian A.Y., DeConti R.C., Conry R., Agarwala S., Papadopoulos N., Kim K.B., Ernstoff M. Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma. Ann. Oncol. 2010, 22(4):787-793.
16. Benezra M., Penate-Medina O., Zanzonico P.B., Schaer D., Ow H., Burns A., DeStanchina E., Longo V., Herz E., Iyer S., Wolchok J., Larson S.M., Wiesner U., Bradbury M.S. Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma. Eur. J. Clin. Invest. 2011, 121(7):2768-2780.
17. Beutel G., Glen H., Schöffski P., Chick J., Gill S., Cassidy J., Twelves C. Phase I study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor in patients with refractory solid tumors. Clin. Cancer Res. 2005, 11(15):5487-5495.
18. Bissett D., Cassidy J., de Bono J.S., Muirhead F., Main M., Robson L., Fraier D., Magnè M.L., Pellizzoni C., Porro M.G., Spinelli R., Speed W., Twelves C. Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT). Br. J. Cancer 2004, 91(1):50-55.
19. Bolling C., Graefe T., Lübbing C., Jankevicius F., Uktveris S., Cesas A., Meyer-Moldenhauer W., Starkmann H., Weigel M., Burk K., Hanauske A. Phase II study of MTX-HSA in combination with Cisplatin as first line treatment in patients with advanced or metastatic transitional cell carcinoma. Invest. New Drugs 2006, 24(6):521-527.
20. Boorjian S.A., Milowsky M.I., Kaplan J., Albert M., Cobham M.V., Coll D.M., Mongan N.P., Shelton G., Petrylak D., Gudas L.J., Nanus D.M. Phase 1/2 clinical trial of interferon alpha2b and weekly liposome-encapsulated all-trans retinoic acid in patients with advanced renal cell carcinoma. J. Immunother. 2007, 30(6):655-662.
21. Booser D., Esteva F., Rivera E., Valero V., Esparza-Guerra L., Priebe W., Hortobagyi G. Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancer. Cancer Chemother. Pharmacol. 2002, 50(1):6-8.
22. Bouchie A. First microRNA mimic enters clinic. Nat. Biotechnol. 2013, 31(7):577.
23. Boyraz B., Sendur M.A.N., Aksoy S., Babacan T., Roach E.C., Kizilarslanoglu M.C., Petekkaya I., Altundag K. Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer. Curr. Med. Res. Opin. 2013, 29(4):405-414.
24. Bozzuto G., Molinari A. Liposomes as nanomedical devices. Int. J. Nanomed. 2015, 10:975-999.
25. Bross P.F., Beitz J., Chen G., Chen X.H., Duffy E., Kieffer L., Roy S., Sridhara R., Rahman A., Williams G., Pazdur R. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin. Cancer Res. 2001, 7(6):1490-1496.
26. Burnett J.C., Rossi J.J., Tiemann K. Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol. J. 2011, 6(9):1130-1146.
27. Burris H.A., Rugo H.S., Vukelja S.J., Vogel C.L., Borson R.A., Limentani S., Tan-Chiu E., Krop I.E., Michaelson R.A., Girish S., Amler L., Zheng M., Chu Y.W., Klencke B., O'Shaughnessy J.A. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J. Clin. Oncol. 2011, 29(4):398-405.
28. Butts C., Maksymiuk A., Goss G., Soulières D., Marshall E., Cormier Y., Ellis P., Price A., Sawhney R., Beier F., Falk M., Murray N. Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial. J. Cancer Res. Clin. Oncol. 2011, 137(9):1337-1342.
29. Byrne J.D., Betancourt T., Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv. Drug Deliv. Rev. 2008, 60(15):1615-1626.
30. Calvo E., Hoch U., Maslyar D.J., Tolcher A.W. Dose-escalation phase I study of NKTR-105, a novel pegylated form of docetaxel. J. Clin. Oncol. 2010, 28(15 s):TPS160.
31. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology 2005, 69(Suppl. 3):4-10.
32. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature 2000, 407(6801):249-257.
33. Chabner B.A., Roberts T.G. Chemotherapy and the war on cancer. Nat. Rev. Cancer 2005, 5(1):65-72.
34. Chang S.S. Overview of prostate-specific membrane antigen. Rev. Urol. 2004, 6:S13-S18.
35. Chen H., Gao J., Lu Y., Kou G., Zhang H., Fan L., Sun Z., Guo Y., Zhong Y. Preparation and characterization of PE38KDEL-loaded anti-HER2 nanoparticles for targeted cancer therapy. J. Control. Release 2008, 128(3):209-216.
36. Chen K., Xie J., Xu H., Behera D., Michalski M.H., Biswal S., Wang A., Chen X. Triblock copolymer coated iron oxide nanoparticle conjugate for tumor integrin targeting. Biomaterials 2009, 30(36):6912-6919.
37. Chen Z., Nie S., Shin D.M. A folate receptor-targeting nanoparticle minimizes drug resistance in a human cancer model. ACS Nano 2011, 5(8):6184-6194.
38. Chittasupho C., Xie S., Baoum A., Yakovleva T., Siahaan T.J., Berkland C.J. ICAM-1 targeting of doxorubicin-loaded PLGA nanoparticles to lung epithelial cells. Eur. J. Pharm. Sci. 2009, 37(2):141-150.
39. Cho K., Wang X., Nie S., Chen Z., Shin D.M. Therapeutic nanoparticles for drug delivery in cancer. Clin. Cancer Res. 2008, 14(5):1310-1316.
40. Choi C.H.J., Alabi C.A., Webster P., Davis M.E. Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles. Proc. Natil. Acad. Sci. 2010, 107(3):1235-1240.
41. Choi K.Y., Saravanakumar G., Park J.H., Park K. Hyaluronic acid-based nanocarriers for intracellular targeting: interfacial interactions with proteins in cancer. Colloids Surf. B 2012, 99:82-94.
42. Chou L.Y.T., Ming K., Chan W.C.W. Strategies for the intracellular delivery of nanoparticles. Chem. Soc. Rev. 2011, 40(1):233-245.
43. Christian S., Pilch J., Akerman M.E., Porkka K., Laakkonen P., Ruoslahti E. Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels. J. Cell Biol. 2003, 163(4):871-878.
44. Cirstoiu-Hapca A., Buchegger F., Bossy L., Kosinski M., Gurny R., Delie F. Nanomedicines for active targeting: physico-chemical characterization of paclitaxel-loaded anti-HER2 immunonanoparticles and in vitro functional studies on target cells. Eur. J. Pharm. Sci. 2009, 38(3):230-237.
45. Cirstoiu-Hapca A., Buchegger F., Lange N., Bossy L., Gurny R., Delie F. Benefit of anti-HER2-coated paclitaxel-loaded immuno-nanoparticles in the treatment of disseminated ovarian cancer: therapeutic efficacy and biodistribution in mice. J. Control. Release 2010, 144(3):324-331.
46. Cui Y., Xu Q., Chow P.K., Wang D., Wang C. Transferrin-conjugated magnetic silica PLGA nanoparticles loaded with doxorubicin and paclitaxel for brain glioma treatment. Biomaterials 2013, 34(33):8511-8520.
47. Danhauser-Riedl S., Hausmann E., Schick H.D., Bender R., Dietzfelbinger H., Rastetter J., Hanauske A.R. Phase I clinical and pharmacokinetic trial of dextran conjugated doxorubicin (AD-70, DOX-OXD). Invest. New Drugs 1993, 11(2-3):187-195.
48. Danhier F., Feron O., Preat V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J. Control. Release 2010, 148(2):135-146.
49. Danquah M.K., Zhang X.A., Mahato R.I. Extravasation of polymeric nanomedicines across tumor vasculature. Adv. Drug Deliv. Rev. 2011, 63(8):623-639.
50. Davis M.E. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol. Pharm. 2009, 6:659-668.
51. Davis M.E., Chen Z.G., Shin D.M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov. 2008, 7(9):771-782.
52. Davis M.E., Zuckerman J.E., Choi C.H., Seligson D., Tolcher A., Alabi C.A., Yen Y., Heidel J.D., Ribas A. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010, 464(7291):1067-1070.
53. de Jonge M.J., Slingerland M., Loos W.J., Wiemer E.A., Burger H., Mathijssen R.H., Kroep J.R., den Hollander M.A., van der Biessen D., Lam M.H., Verweij J., Gelderblom H. Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation. Eur. J. Cancer 2010, 46(16):3016-3021.
54. De Mattos-Arruda L., Cortes J. Use of pertuzumab for the treatment of HER2-positive metastatic breast cancer. Adv. Ther. 2013, 30(7):645-658.
55. Deeken J.F., Slack R., Weiss G.J., Ramanathan R.K., Pishvaian M.J., Hwang J., Lewandowski K., Subramaniam D., He A.R., Cotarla I., Rahman A., Marshall J.L. A phase I study of liposomal-encapsulated docetaxel (LE-DT) in patients with advanced solid tumor malignancies. Cancer Chemother. Pharmacol. 2012, 71(3):627-633.
56. Desai N., Trieu V., Yao Z., Louie L., Ci S., Yang A., Tao C., De T., Beals B., Dykes D., Noker P., Yao R., Labao E., Hawkins M., Soon-Shiong P. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin. Cancer Res. 2006, 12(4):1317-1324.
57. Desgrosellier J.S., Cheresh D.A. Integrins in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer 2010, 10(1):9-22.
58. Dhar S., Gu F.X., Langer R., Farokhzad O.C., Lippard S.J. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc. Natl. Acad. Sci. USA 2008, 105(45):17356-17361.
59. Dhar S., Kolishetti N., Lippard S.J., Farokhzad O.C. Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo. Proc. Natl. Acad. Sci. USA 2011, 108(5):1850-1855.
60. Dinndorf P.A., Gootenberg J., Cohen M.H., Keegan P., Pazdur R. FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL). Oncologist 2007, 12(8):991-998.
61. Dixit N., Vaibhav K., Pandey R.S., Jain U.K., Katare O.P., Katyal A., Madan J. Improved cisplatin delivery in cervical cancer cells by utilizing folate-grafted non-aggregated gelatin nanoparticles. Biomed. Pharmacother. 2015, 69:1-10.
62. Dragovich T., Mendelson D., Kurtin S., Richardson K., Von Hoff D., Hoos A. A phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer. Cancer Chemother. Pharmacol. 2006, 58(6):759-764.
63. Dritschilo A., Huang C.H., Rudin C.M., Marshall J., Collins B., Dul J.L., Zhang C., Kumar D., Gokhale P.C., Ahmad A., Ahmad I., Sherman J.W., Kasid U.N. Phase I study of liposome-encapsulated c-raf antisense oligodeoxyribonucleotide infusion in combination with radiation therapy in patients with advanced malignancies. Clin. Cancer Res. 2006, 12(4):1251-1259.
64. Dubey R.D., Alam N., Saneja A., Khare V., Kumar A., Vaidh S., Mahajan G., Sharma P.R., Singh S.K., Mondhe D.M., Gupta P.N. Development and evaluation of folate functionalized albumin nanoparticles for targeted delivery of gemcitabine. Int. J. Pharm. 2015, 492(1-2):80-91.
65. Duffaud F., Borner M., Chollet P., Vermorken J.B., Bloch J., Degardin M., Rolland F., Dittrich C., Baron B., Lacombe D., Fumoleau P. Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck: an EORTC new drug development group study. Eur. J. Cancer 2004, 40(18):2748-2752.
66. Duncan R. The dawning era of polymer therapeutics. Nat. Rev. Drug Discov. 2003, 2(5):347-360.
67. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat. Rev. Cancer 2006, 6(9):688-701.
68. Egusquiaguirre S.P., Igartua M., Hernandez R.M., Pedraz J.L. Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research. Clin. Trans. Oncol. 2012, 14(2):83-93.
69. Farokhzad O.C., Jon S., Khademhosseini A., Tran T.T., LaVan D.A., Langer R. Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res. 2004, 64(21):7668-7672.
70. Farokhzad O.C., Cheng J., Teply B.A., Sherifi I., Jon S., Kantoff P.W., Richie J.P., Langer R. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc. Natl. Acad. Sci. USA 2006, 103(16):6315-6320.
71. Feldman E.J., Lancet J.E., Kolitz J.E., Ritchie E.K., Roboz G.J., List A.F., Allen S.L., Asatiani E., Mayer L.D., Swenson C., Louie A.C. First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. J. Clin. Oncol. 2011, 29:979-985.
72. Feldman E.J., Kolitz J.E., Trang J.M., Liboiron B.D., Swenson C.E., Chiarella M.T., Mayer L.D., Louie A.C., Lancet J.E. Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia. Leuk. Res. 2012, 36(10):1283-1289.
73. Ferlay, J., Soerjomataram, I., Ervik, M., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D.M., Forman, D., Bray, F., 2013. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. International Agency for Research on Cancer, Lyon, France. Available from: . http://globocan.iarc.fr.
74. Ferrara N., Gerber H., LeCouter J. The biology of VEGF and its receptors. Nat. Med. 2003, 9(6):669-676.
75. Fleige E., Quadir M.A., Haag R. Stimuli-responsive polymeric nanocarriers for the controlled transport of active compounds: concepts and applications. Adv. Drug Deliv. Rev. 2012, 64(9):866-884.
76. Fortuin A.S., Meijer H., Thompson L.C., Alfred Witjes J., Barentsz J.O. Ferumoxtran-10 ultrasmall superparamagnetic iron oxide-enhanced diffusion-weighted imaging magnetic resonance imaging for detection of metastases in normal-sized lymph nodes in patients with bladder and prostate cancer: do we enter the era after extended pelvic lymph node dissection?. Eur. Urol. 2013, 64(6):961-963.
77. Gabizon A.A., Tzemach D., Horowitz A.T., Shmeeda H., Yeh J., Zalipsky S. Reduced toxicity and superior therapeutic activity of a mitomycin C lipid-based prodrug incorporated in pegylated liposomes. Clin. Cancer Res. 2006, 12(6):1913-1920.
78. Gaillard P.J., Appeldoorn C.C.M., Dorland R., van Kregten J., Manca F., Vugts D.J., Windhorst B., van Dongen G.A.M.S., de Vries H.E., Maussang D., van Tellingen O. Pharmacokinetics, brain delivery, and efficacy in brain tumor-bearing mice of glutathione pegylated liposomal doxorubicin (2B3-101). PLoS One 2013, 9(1):e82331.
79. Gan C.W., Feng S.S. Transferrin-conjugated nanoparticles of poly(lactide)-d-alpha-tocopheryl polyethylene glycol succinate diblock copolymer for targeted drug delivery across the blood-brain barrier. Biomaterials 2010, 31(30):7748-7757.
80. Gaur S., Wang Y., Kretzner L., Chen L., Yen T., Wu X., Yuan Y., Davis M., Yen Y. Pharmacodynamic and pharmacogenomic study of the nanoparticle conjugate of camptothecin CRLX101 for the treatment of cancer. Nanomedicine 2014, 10(7):1477-1486.
81. Geretti E., Leonard S.C., Dumont N., Lee H., Zheng J., De Souza R., Gaddy D.F., Espelin C.W., Jaffray D.A., Moyo V., Nielsen U.B., Wickham T.J., Hendriks B.S. Cyclophosphamide-mediated tumor priming for enhanced delivery and anti-tumor activity of HER2-targeted liposomal doxorubicin (MM-302). Mol. Cancer Ther. 2015, 14:2060-2071.
82. Ghamande S., Lin C., Cho D., Shapiro G., Kwak E., Silverman M., Tseng Y., Kuo M., Mach W., Hsu S., Coleman T., Yang J., Cheng A., Ghalib M., Chuadhary I., Goel S. A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors. Invest. New Drugs 2014, 32(3):445-451.
83. Giles F.J., Kantarjian H.M., Kornblau S.M., Thomas D.A., Garcia-Manero G., Waddelow T.A., David C.L., Phan A.T., Colburn D.E., Rashid A., Estey EH Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer 2001, 92(2):406-413.
84. Glantz M.J., Jaeckle K.A., Chamberlain M.C., Phuphanich S., Recht L., Swinnen L.J., Maria B., LaFollette S., Schumann G.B., Cole B.F., Howell S.B. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin. Cancer Res. 1999, 5(11):3394-3402.
85. Gonzalez-Angulo A.M., Meric-Bernstam F., Chawla S., Falchook G., Hong D., Akcakanat A., Chen H., Naing A., Fu S., Wheler J., Moulder S., Helgason T., Li S., Elias I., Desai N., Kurzrock R. Weekly nab-Rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trial. Clin. Cancer Res. 2013, 19(19):5474-5484.
86. Goodarzi N., Varshochian R., Kamalinia G., Atyabi F., Dinarvand R. A review of polysaccharide cytotoxic drug conjugates for cancer therapy. Carbohydr. Polym. 2013, 92(2):1280-1293.
87. Grothey A., Galanis E. Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat. Rev. Clin. Oncol. 2009, 6(9):507-518.
88. Gu F.X., Karnik R., Wang A.Z., Alexis F., Levy-Nissenbaum E., Hong S., Langer R.S., Farokhzad O.C. Targeted nanoparticles for cancer therapy. Nano Today 2007, 2(3):14-21.
89. Gualberto A. Brentuximab vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies. Expert Opin. Investig. Drugs 2012, 21(2):205-216.
90. Guo S., Huang L. Nanoparticles escaping RES and endosome: challenges for siRNA delivery for cancer therapy. J. Nanomater. 2011, 742895:1-12.
91. Guo J., Gao X., Su L., Xia H., Gu G., Pang Z., Jiang X., Yao L., Chen J., Chen H. Aptamer-functionalized PEG-PLGA nanoparticles for enhanced anti-glioma drug delivery. Biomaterials 2011, 32(31):8010-8020.
92. Guo Y., Wang L., Lv P., Zhang P. Transferrin-conjugated doxorubicin-loaded lipid-coated nanoparticles for the targeting and therapy of lung cancer. Oncol. Lett. 2015, 9(3):1065-1072.
93. Hadjipanayis C.G., Machaidze R., Kaluzova M., Wang L., Schuette A.J., Chen H., Wu X., Mao H. EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma. Cancer Res. 2010, 70(15):6303-6312.
94. Hamaguchi T. A phase I and pharmacokinetic study of NK105, a paclitaxel incorporating micellar nanoparticle formulation. Br. J. Cancer 2007, 97:170-176.
95. Hamaguchi T., Doi T., Eguchi-Nakajima T., Kato K., Yamada Y., Shimada Y., Fuse N., Ohtsu A., Matsumoto S., Takanashi M., Matsumura Y. Phase I study of NK012, a novel SN-38-incorporating micellar nanoparticle, in adult patients with solid tumors. Clin. Cancer Res. 2010, 16(20):5058-5066.
96. Han H.D., Mangala L.S., Lee J.W., Shahzad M.M., Kim H.S., Shen D., Nam E.J., Mora E.M., Stone R.L., Lu C., Lee S.J., Roh J.W., Nick A.M., Lopez-Berestein G., Sood A.K. Targeted gene silencing using RGD-labeled chitosan nanoparticles. Clin. Cancer Res. 2010, 16(15):3910-3922.
97. Hanahan D., Weinberg R. Hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674.
98. Harada M., Bobe I., Saito H., Shibata N., Tanaka R., Hayashi T., Kato Y. Improved anti-tumor activity of stabilized anthracycline polymeric micelle formulation, NC-6300. Cancer Sci. 2011, 102(1):192-199.
99. Harris R.C., Chung E., Coffey R.J. EGF receptor ligands. Exp. Cell Res. 2003, 284(1):2-13.
100. Harrison M., Tomlinson D., Stewart S. Liposomal-entrapped doxorubicin: an active agent in AIDS-related Kaposi's sarcoma. J. Clin. Oncol. 1995, 13(4):914-920.
101. Hawkins M.J., Soon-Shiong P., Desai N. Protein nanoparticles as drug carriers in clinical medicine. Adv. Drug Deliv. Rev. 2008, 60(8):876-885.
102. Hedgire S.S., Mino-Kenudson M., Elmi A., Thayer S., Fernandez-del Castillo C., Harisinghani M.G. Enhanced primary tumor delineation in pancreatic adenocarcinoma using ultrasmall super paramagnetic iron oxide nanoparticle-ferumoxytol: an initial experience with histopathologic correlation. Int. J. Nanomed. 2014, 9:1891-1896.
103. Hilgenbrink A.R., Low P.S. Folate receptor-mediated drug targeting: from therapeutics to diagnostics. J. Pharm. Sci. 2005, 94(10):2135-2146.
104. Holbro T., Civenni G., Hynes N.E. The ErbB receptors and their role in cancer progression. Exp. Cell Res. 2003, 284(1):99-110.
105. Homsi J., Simon G.R., Garrett C.R., Springett G., De Conti R., Chiappori A.A., Munster P.N., Burton M.K., Stromatt S., Allievi C., Angiuli P., Eisenfeld A., Sullivan D.M., Daud A.I. Phase I trial of poly-l-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies. Clin. Cancer Res. 2007, 13(19):5855-5861.
106. Hong M., Zhu S., Jiang Y., Tang G., Sun C., Fang C., Shi B., Pei Y. Novel anti-tumor strategy: PEG-hydroxycamptothecin conjugate loaded transferrin-PEG-nanoparticles. J. Control. Release 2010, 141(1):22-29.
107. Hrkach J., Von Hoff D., Ali M.M., Andrianova E., Auer J., Campbell T., De Witt D., Figa M., Figueiredo M., Horhota A., Low S., McDonnell K., Peeke E., Retnarajan B., Sabnis A., Schnipper E., Song J.J., Song Y.H., Summa J., Tompsett D., Troiano G., Van G.H., Wright J., LoRusso P., Kantoff P.W., Bander N.H., Sweeney C., Farokhzad O.C., Langer R., Zale S. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci. Trans. Med. 2012, 4(128):128ra39.
108. Hsieh W., Liang C., Chieh J., Wang S., Lai I., Chen J., Chang F., Tseng W., Yang S., Wu C., Chen Y. In vivo tumor targeting and imaging with anti-vascular endothelial growth factor antibody-conjugated dextran-coated iron oxide nanoparticles. Int. J. Nanomed. 2012, 7:2833-2842.
109. Hu C.M., Aryal S., Zhang L. Nanoparticle-assisted combination therapies for effective cancer treatment. Ther. Deliv. 2010, 1(2):323-334.
110. Huang H., Barua S., Sharma G., Dey S.K., Rege K. Inorganic nanoparticles for cancer imaging and therapy. J. Control. Release 2011, 155(3):344-357.
111. Hwang J.H., Lim M.C., Seo S., Park S., Kang S. Phase II study of belotecan (CKD 602) as a single agent in patients with recurrent or progressive carcinoma of uterine cervix. Jpn. J. Clin. Oncol. 2011, 41(5):624-629.
112. Infante J., Keedy V., Jones S., Zamboni W., Chan E., Bendell J., Lee W., Wu H., Ikeda S., Kodaira H., Rothenberg M., Burris H. Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 2012, 70(5):699-705.
113. Jain R.K., Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat. Rev. Clin. Oncol. 2010, 7(11):653-664.
114. Jain A., Chasoo G., Singh S.K., Saxena A.K., Jain S.K. Transferrin-appended PEGylated nanoparticles for temozolomide delivery to brain: in vitro characterisation. J. Microencapsul. 2011, 28(1):21-28.
115. Jeelani S., Reddy R.C.J., Maheswaran T., Asokan G.S., Dany A., Anand B. Theranostics: a treasured tailor for tomorrow. J. Pharm. Bioall. Sci. 2014, 6:S6-S8.
116. Jhaveri A., Deshpande P., Torchilin V. Stimuli-sensitive nanopreparations for combination cancer therapy. J. Control. Release 2014, 190:352-370.
117. Ji S., Xu J., Zhang B., Yao W., Xu W., Wu W., Xu Y., Wang H., Ni Q., Hou H., Yu X. RGD-conjugated albumin nanoparticles as a novel delivery vehicle in pancreatic cancer therapy. Cancer Biol. Ther. 2012, 13(4):206-215.
118. Judge A.D., Robbins M., Tavakoli I., Levi J., Hu L., Fronda A., Ambegia E., McClintock K., MacLachlan I. Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. Eur. J. Clin. Invest. 2009, 119(3):661-673.
119. Karkada M., Berinstein N.L., Mansour M. Therapeutic vaccines and cancer: focus on DPX-0907. Biologics 2014, 8:27-38.
120. Karra N., Nassar T., Ripin A.N., Schwob O., Borlak J., Benita S. Antibody conjugated PLGA nanoparticles for targeted delivery of paclitaxel palmitate: efficacy and biofate in a lung cancer mouse model. Small 2013, 9(24):4221-4236.
121. Kato K., Chin K., Yoshikawa T., Yamaguchi K., Tsuji Y., Esaki T., Sakai K., Kimura M., Hamaguchi T., Shimada Y., Matsumura Y., Ikeda R. Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer. Invest. New Drugs 2012, 30(4):1621-1627.
122. Khemapech N., Oranratanaphan S., Termrungruanglert W., Lertkhachonsuk R., Vasurattana A. Salvage chemotherapy in recurrent platinum-resistant or refractory epithelial ovarian cancer with Carboplatin and distearoylphosphatidylcholine pegylated liposomal Doxorubicin (lipo-dox®). Asian Pac. J. Cancer Prev. 2013, 14(3):2131-2135.
123. Kirpotin D.B., Drummond D.C., Shao Y., Shalaby M.R., Hong K., Nielsen U.B., Marks J.D., Benz C.C., Park J.W. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 2006, 66(13):6732-6740.
124. Ko A.H., Tempero M.A., Shan Y., Su W., Lin Y., Dito E., Ong A., Wang Y., Yeh C.G., Chen L. A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer. Br. J. Cancer 2013, 109(4):920-925.
125. Kono K. Thermosensitive polymer-modified liposomes. Adv. Drug Deliv. Rev. 2001, 53(3):307-319.
126. Koshkaryev A., Sawant R., Deshpande M., Torchilin V. Immunoconjugates and long circulating systems: origins, current state of the art and future directions. Adv. Drug Deliv. Rev. 2013, 65(1):24-35.
127. Kottschade L.A., Suman V.J., Amatruda T., McWilliams R.R., Mattar B.I., Nikcevich D.A., Behrens R., Fitch T.R., Jaslowski A.J., Markovic S.N. A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma: A North Central Cancer Treatment Group Study, N057E. Cancer 2010, 117(8):1704-1710.
128. Kovalainen M., Monkare J., Kaasalainen M., Riikonen J., Lehto V.P., Salonen J., Herzig K.H., Jarvinen K. Development of porous silicon nanocarriers for parenteral peptide delivery. Mol. Pharm. 2013, 10(1):353-359.
129. Kroemer G., Zitvogel L., Galluzzi L. Victories and deceptions in tumor immunology: Stimuvax®. Oncoimmunology 2013, 2(1):e23687.
130. Krown S.E., Northfelt D.W., Osoba D., Stewart J.S. Use of liposomal anthracyclines in Kaposi's sarcoma. Semin. Oncol. 2004, 31(6 Suppl. 13):36-52.
131. Kullberg M., Mann K., Anchordoquy T.J. Targeting Her-2+ breast cancer cells with bleomycin immunoliposomes linked to LLO. Mol. Pharm. 2012, 9(7):2000-2008.
132. Kwon G.S. Polymeric micelles for delivery of poorly water-soluble compounds. Crit. Rev. Ther. Drug Carrier Syst. 2003, 20(5):357-403.
133. Lambert J.M. Drug-conjugated antibodies for the treatment of cancer. Br. J. Clin. Pharmacol. 2013, 76(2):248-262.
134. Landen C.N., Chavez-Reyes A., Bucana C., Schmandt R., Deavers M.T., Lopez-Berestein G., Sood A.K. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res. 2005, 65(15):6910-6918.
135. Langer C.J., O'Byrne K.J., Socinski M.A., Mikhailov S.M., Lesniewski-Kmak K., Smakal M., Ciuleanu T.E., Orlov S.V., Dediu M., Heigener D., Eisenfeld A.J., Sandalic L., Oldham F.B., Singer J.W., Ross H.J. Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer. J. Thorac. Oncol. 2008, 3(6):623-630.
136. Lao Y., Phua K.K.L., Leong K.W. Aptamer nanomedicine for cancer therapeutics: barriers and potential for translation. ACS Nano 2015, 9(3):2235-2254.
137. Laudadio J., Quigley D.I., Tubbs R., Wolff D.J. HER2 testing: a review of detection methodologies and their clinical performance. Expert Rev. Mol. Diagn. 2007, 7(1):53-64.
138. Leamon C.P., Low P.S. Folate-mediated targeting: from diagnostics to drug and gene delivery. Drug Discov. Today 2001, 6(1):44-51.
139. Lee K.S., Chung H.C., Im S.A., Park Y.H., Kim C.S., Kim S.B., Rha S.Y., Lee M.Y., Ro J. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res. Treat. 2008, 108(2):241-250.
140. Lee J.H., Lee K., Moon S.H., Lee Y., Park T.G., Cheon J. All-in-one target-cell-specific magnetic nanoparticles for simultaneous molecular imaging and siRNA delivery. Angew. Chem. Int. Ed. 2009, 48(23):4174-4179.
141. Lee S., Yun M., Jeong S.W., In C., Kim J., Seo M., Pai C., Kim S. Development of docetaxel-loaded intravenous formulation, Nanoxel-PM™ using polymer-based delivery system. J. Control. Release 2011, 155(2):262-271.
142. Lee S.H., Jeong D., Han Y.S., Baek M.J. Pivotal role of vascular endothelial growth factor pathway in tumor angiogenesis. Ann. Surg. Treat. Res. 2015, 89(1):1-8.
143. Letchford K., Burt H. A review of the formation and classification of amphiphilic block copolymer nanoparticulate structures: micelles, nanospheres, nanocapsules and polymersomes. Eur. J. Pharm. Biopharm. 2007, 65(3):259-269.
144. Li H., Qian Z.M. Transferrin/transferrin receptor-mediated drug delivery. Med. Res. Rev. 2002, 22(3):225-250.
145. Li Z., Rana T.M. Therapeutic targeting of microRNAs: current status and future challenges. Nat. Rev. Drug Discov. 2014, 13(8):622-638.
146. Li J., Gupta S., Li C. Research perspectives: gold nanoparticles in cancer theranostics. Quant. Imaging Med. Surg. 2013, 3(6):284-291.
147. Libutti S.K., Paciotti G.F., Byrnes A.A., Alexander H.R., Gannon W.E., Walker M., Seidel G.D., Yuldasheva N., Tamarkin L. Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine. Clin. Cancer Res. 2010, 16(24):6139-6149.
148. ®-PM) in patients with solid tumors. Ann. Oncol. 2010, 21(2):382-388.
149. Liu Z., Jiao Y., Wang Y., Zhou C., Zhang Z. Polysaccharides-based nanoparticles as drug delivery systems. Adv. Drug Deliv. Rev. 2008, 60(15):1650-1662.
150. Liu D., Liu F., Liu Z., Wang L., Zhang N. Tumor specific delivery and therapy by double-targeted nanostructured lipid carriers with anti-VEGFR-2 antibody. Mol. Pharm. 2011, 8(6):2291-2301.
151. Liu P., Qi X., Sun Y., Wang H., Li Y., Duan Y. RGD-conjugated PLA-PLL nanoparticles targeting to Bacp-37 breast cancer xenografts in vivo. J. Nanosci. Nanotechnol. 2011, 11(12):10760-10764.
152. Low P.S., Antony A.C. Folate receptor-targeted drugs for cancer and inflammatory diseases. Adv. Drug Deliv. Rev. 2004, 56(8):1055-1058.
153. Low P.S., Kularatne S.A. Folate-targeted therapeutic and imaging agents for cancer. Curr. Opin. Chem. Biol. 2009, 13(3):256-262.
154. Low P.S., Henne W.A., Doorneweerd D.D. Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases. Acc. Chem. Res. 2008, 41(1):120-129.
155. Lu C., Stewart D.J., Lee J.J., Ji L., Ramesh R., Jayachandran G., Nunez M.I., Wistuba I.I., Erasmus J.J., Hicks M.E., Grimm E.A., Reuben J.M., Baladandayuthapani V., Templeton N.S., McMannis J.D., Roth J.A. Phase I clinical trial of systemically administered TUSC2(FUS1)-nanoparticles mediating functional gene transfer in humans. PLoS One 2012, 7(4):e34833.
156. Lu J., Zhao W., Huang Y., Liu H., Marquez R., Gibbs R.B., Li J., Venkataramanan R., Xu L., Li S., Li S. Targeted delivery of Doxorubicin by folic acid-decorated dual functional nanocarrier. Mol. Pharm. 2014, 11(11):4164-4178.
157. Lurje G., Lenz H. EGFR signaling and drug discovery. Oncology 2009, 77(6):400-410.
158. Madaan A., Singh P., Awasthi A., Verma R., Singh A., Jaggi M., Mishra S., Kulkarni S., Kulkarni H. Efficiency and mechanism of intracellular paclitaxel delivery by novel nanopolymer-based tumor-targeted delivery system, Nanoxel™. Clin. Transl. Oncol. 2013, 15(1):26-32.
159. Maeda H. SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv. Drug Deliv. Rev. 2001, 46(1-3):169-185.
160. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release 2000, 65(1-2):271-284.
161. Maeda H., Nakamura H., Fang J. The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv. Drug Deliv. Rev. 2013, 65(1):71-79.
162. Maggiorella L., Barouch G., Devaux C., Pottier A., Deutsch E., Bourhis J., Borghi E., Levy L. Nanoscale radiotherapy with hafnium oxide nanoparticles. Future Oncol. 2012, 8(9):1167-1181.
163. Mahalingam D., Nemunaitis J., Malik L., Sarantopoulos J., Weitman S., Sankhala K., Hart J., Kousba A., Gallegos N., Anderson G., Charles J., Rogers J., Senzer N., Mita A. Phase I study of intravenously administered ATI-1123, a liposomal docetaxel formulation in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 2014, 74(6):1241-1250.
164. Mamot C., Drummond D.C., Greiser U., Hong K., Kirpotin D.B., Marks J.D., Park J.W. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. Cancer Res. 2003, 63(12):3154-3161.
165. Mamot C., Drummond D.C., Noble C.O., Kallab V., Guo Z., Hong K., Kirpotin D.B., Park J.W. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res. 2005, 65(24):11631-11638.
166. Mamot C., Ritschard R., Wicki A., Küng W., Schuller J., Herrmann R., Rochlitz C. Immunoliposomal delivery of doxorubicin can overcome multidrug resistance mechanisms in EGFR-overexpressing tumor cells. J. Drug Target. 2012, 20(5):422-432.
167. Mamot C., Ritschard R., Wicki A., Stehle G., Dieterle T., Bubendorf L., Hilker C., Deuster S., Herrmann R., Rochlitz C. Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study. Lancet Oncol. 2012, 13(12):1234-1241.
168. Masetti R., Pession A. First-line treatment of acute lymphoblastic leukemia with pegasparaginase. Biologics 2009, 3:359-368.
169. Matabudul D., Pucaj K., Bolger G., Vcelar B., Majeed M., Helson L. Tissue distribution of (Lipocurc) liposomal curcumin and tetrahydrocurcumin following two- and eight-hour infusions in Beagle dogs. Anticancer Res. 2012, 32(10):4359-4364.
170. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986, 46(12 Part 1):6387-6392.
171. Matsumura Y., Gotoh M., Muro K., Yamada Y., Shirao K., Shimada Y., Okuwa M., Matsumoto S., Miyata Y., Ohkura H., Chin K., Baba S., Yamao T., Kannami A., Takamatsu Y., Ito K., Takahashi K. Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer. Ann. Oncol. 2004, 15(3):517-525.
172. Matsumura Y., Hamaguchi T., Ura T., Muro K., Yamada Y., Shimada Y., Shirao K., Okusaka T., Ueno H., Ikeda M., Watanabe N. Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. Br. J. Cancer 2004, 91(10):1775-1781.
173. McDonagh C.F., Huhalov A., Harms B.D., Adams S., Paragas V., Oyama S., Zhang B., Luus L., Overland R., Nguyen S., Gu J., Kohli N., Wallace M., Feldhaus M.J., Kudla A.J., Schoeberl B., Nielsen U.B. Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3. Mol. Cancer Ther. 2012, 11(3):582-593.
174. Meerum Terwogt J.M., ten Bokkel Huinink W.W., Schellens J.H., Schot M., Mandjes I.A., Zurlo M.G., Rocchetti M., Rosing H., Koopman F.J., Beijnen J.H. Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel. Anticancer Drugs 2001, 12(4):315-323.
175. Miele E., Spinelli G.P., Miele E., Tomao F., Tomao S. Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer. Int. J. Nanomed. 2009, 4:99-105.
176. Milane L., Duan Z., Amiji M. Therapeutic efficacy and safety of paclitaxel/lonidamine loaded EGFR-targeted nanoparticles for the treatment of multi-drug resistant cancer. PLoS One 2011, 6(9):e24075.
177. Miller S.M., Wang A.Z. Nanomedicine in chemoradiation. Ther. Deliv. 2013, 4(2):239-250.
178. Misra R., Sahoo S.K. Intracellular trafficking of nuclear localization signal conjugated nanoparticles for cancer therapy. Eur. J. Pharm. Sci. 2010, 39(1-3):152-163.
179. Mitragotri S. Foreword. Nanoparticulate Drug Delivery: Perspectives on the Transitition From Laboratory to Market 2012, Woodhead Publishing Ltd, Cambridge, MA, pp. XIII-XIV.
180. Moasser M.M., Krop I.E. The evolving landscape of HER2 targeting in breast cancer. JAMA Oncol. 2015, 1:1154-1161.
181. Morral-Ruíz G., Melgar-Lesmes P., López-Vicente A., Solans C., García-Celma M. Biotinylated polyurethane-urea nanoparticles for targeted theranostics in human hepatocellular carcinoma. Nano Res. 2015, 8(5):1729-1745.
182. Mu K., Zhang S., Ai T., Jiang J., Yao Y., Jiang L., Zhou Q., Xiang H., Zhu Y., Yang X., Zhu W. Monoclonal antibody-conjugated superparamagnetic iron oxide nanoparticles for imaging of epidermal growth factor receptor-targeted cells and gliomas. Mol. Imaging 2015, 14:2-12.
183. Muggia F.M., Hainsworth J.D., Jeffers S., Miller P., Groshen S., Tan M., Roman L., Uziely B., Muderspach L., Garcia A., Burnett A., Greco F.A., Morrow C.P., Paradiso L.J., Liang L.J. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J. Clin. Oncol. 1997, 15(3):987-993.
184. Muller C., Schibli R. Prospects in folate receptor-targeted radionuclide therapy. Front. Oncol. 2013, 3:249.
185. Na K., Bum Lee T., Park K., Shin E., Lee Y., Choi H. Self-assembled nanoparticles of hydrophobically-modified polysaccharide bearing vitamin H as a targeted anti-cancer drug delivery system. Eur. J. Pharm. Sci. 2003, 18(2):165-173.
186. Needham D. Materials engineering of lipid bilayers for drug carrier performance. MRS Bull. 1999, 24:32-41.
187. Needham D., Dewhirst M.W. The development and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors. Adv. Drug Deliv. Rev. 2001, 53(3):285-305.
188. Nowotnik D.P., Cvitkovic E. ProLindac™ (AP5346): a review of the development of an HPMA DACH platinum polymer therapeutic. Adv. Drug Deliv. Rev. 2009, 61(13):1214-1219.
189. Orleth A., Mamot C., Rochlitz C., Ritschard R., Alitalo K., Christofori G., Wicki A. Simultaneous targeting of VEGF-receptors 2 and 3 with immunoliposomes enhances therapeutic efficacy. J. Drug Target. 2016, 24:80-89.
190. Ott P.A., Carvajal R.D., Pandit-Taskar N., Jungbluth A.A., Hoffman E.W., Wu B., Bomalaski J.S., Venhaus R., Pan L., Old L.J., Pavlick A.C., Wolchok J.D. Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma. Invest. New Drugs 2012, 31(2):425-434.
191. Owens D.E., Peppas N.A. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm. 2006, 307(1):93-102.
192. Padera T.P., Stoll B.R., Tooredman J.B., Capen D., di Tomaso E., Jain R.K. Pathology: cancer cells compress intratumour vessels. Nature 2004, 427(6976):695.
193. Pal A., Khan S., Wang Y.F., Kamath N., Sarkar A.K., Ahmad A., Sheikh S., Ali S., Carbonaro D., Zhang A., Ahmad I. Preclinical safety, pharmacokinetics and antitumor efficacy profile of liposome-entrapped SN-38 formulation. Anticancer Res. 2005, 25(1A):331-341.
194. Parveen S., Sahoo S.K. Polymeric nanoparticles for cancer therapy. J. Drug Target. 2008, 16(2):108-123.
195. Parveen S., Sahoo S. Evaluation of cytotoxicity and mechanism of apoptosis of doxorubicin using folate-decorated chitosan nanoparticles for targeted delivery to retinoblastoma. Cancer Nanotechnol. 2010, 1(1-6):47-62.
196. Patnaik A., Papadopoulos K.P., Tolcher A.W., Beeram M., Urien S., Schaaf L.J., Tahiri S., Bekaii-Saab T., Lokiec F.M., Rezaï K., Buchbinder A. Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer. Cancer Chemother. Pharmacol. 2013, 71(6):1499-1506.
197. Pecot C.V., Calin G.A., Coleman R.L., Lopez-Berestein G., Sood A.K. RNA interference in the clinic: challenges and future directions. Nat. Rev. Cancer 2011, 11(1):59-67.
198. Peer D., Karp J.M., Hong S., Farokhzad O.C., Margalit R., Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2007, 2(12):751-760.
199. Pelicano H., Martin D.S., Xu R.H., Huang P. Glycolysis inhibition for anticancer treatment. Oncogene 2006, 25(34):4633-4646.
200. Perez H.L., Cardarelli P.M., Deshpande S., Gangwar S., Schroeder G.M., Vite G.D., Borzilleri R.M. Antibody-drug conjugates: current status and future directions. Drug Discov. Today 2014, 19(7):869-881.
201. Pérez-Herrero E., Fernández-Medarde A. Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy. Eur. J. Pharm. Biopharm. 2015, 93:52-79.
202. Peters C., Brown S. Antibody-drug conjugates as novel anti-cancer chemotherapeutics. Biosci. Rep. 2015, 35(4):e00225.
203. Pfizer, 2013. Pfizer Discontinues Phase 3 Study of Inotuzumab Ozogamicin in Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma (NHL) Due to Futility.
204. Pham A., Chen R. Brentuximab vedotin for the treatment of Hodgkin's lymphoma. Expert Rev. Hematol. 2015, 8(4):403-412.
205. Pirollo K.F., Rait A., Zhou Q., Zhang X.Q., Zhou J., Kim C.S., Benedict W.F., Chang E.H. Tumor-targeting nanocomplex delivery of novel tumor suppressor RB94 chemosensitizes bladder carcinoma cells in vitro and in vivo. Clin. Cancer Res. 2008, 14(7):2190-2198.
206. Plummer R., Wilson R.H., Calvert H., Boddy A.V., Griffin M., Sludden J., Tilby M.J., Eatock M., Pearson D.G., Ottley C.J., Matsumura Y., Kataoka K., Nishiya T. A phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours. Br. J. Cancer 2011, 104(4):593-598.
207. Ponka P., Lok C.N. The transferrin receptor: role in health and disease. Int. J. Biochem. Cell Biol. 1999, 31(10):1111-1137.
208. Poon R.T., Borys N. Lyso-thermosensitive liposomal doxorubicin: an adjuvant to increase the cure rate of radiofrequency ablation in liver cancer. Future Oncol. 2011, 7(8):937-945.
209. Pradhan R., Ramasamy T., Choi J.Y., Kim J.H., Poudel B.K., Tak J.W., Nukolova N., Choi H., Yong C.S., Kim J.O. Hyaluronic acid-decorated poly(lactic-co-glycolic acid) nanoparticles for combined delivery of docetaxel and tanespimycin. Carbohydr. Polym. 2015, 123:313-323.
210. Qi X., Fan Y., He H., Wu Z. Hyaluronic acid-grafted polyamidoamine dendrimers enable long circulation and active tumor targeting simultaneously. Carbohydr. Polym. 2015, 126:231-239.
211. Qian Z.M., Tang P.L. Mechanisms of iron uptake by mammalian cells. Biochim. Biophys. Acta 1995, 1269(3):205-214.
212. Rademaker-Lakhai J.M., Terret C., Howell S.B., Baud C.M., De Boer R.F., Pluim D., Beijnen J.H., Schellens J.H., Droz J.P. A phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors. Clin. Cancer Res. 2004, 10(10):3386-3395.
213. Reichert J.M. Marketed therapeutic antibodies compendium. MAbs 2012, 4(3):413-415.
214. Rettig G.R., Behlke M.A. Progress toward in vivo use of siRNAs-II. Mol. Ther. 2011, 20(3):483-512.
215. Rini B. Future approaches in immunotherapy. Semin. Oncol. 2014, 41(Suppl. 5):S30-S40.
216. Rivera Gil P., Hühn D., del Mercato L.L., Sasse D., Parak W.J. Nanopharmacy: inorganic nanoscale devices as vectors and active compounds. Pharmacol. Res. 2010, 62(2):115-125.
217. Roby, K., Niu, F., Rajewski, R., Decedue, C., Subramaniam, B., Terranova, P., 2008. Syngeneic Mouse Model of Epithelial Ovarian Cancer: Effects of Nanoparticulate Paclitaxel, Nanotax®. In: Coukos, G., Berchuck, A., Ozols, R. (Eds.), Springer, New York, NY, pp. 169-181.
218. Rodriguez M.A., Pytlik R., Kozak T., Chhanabhai M., Gascoyne R., Lu B., Deitcher S.R., Winter J.N. Vincristine sulfate liposomes injection (Marqibo) in heavily pretreated patients with refractory aggressive non-Hodgkin lymphoma: report of the pivotal phase 2 study. Cancer 2009, 115(15):3475-3482. Marqibo Investigators.
219. Ross J.F., Wang H., Behm F.G., Mathew P., Wu M., Booth R., Ratnam M. Folate receptor type beta is a neutrophilic lineage marker and is differentially expressed in myeloid leukemia. Cancer 1999, 85(2):348-357.
220. Rowe J.M., Löwenberg B. Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug. Blood 2013, 121(24):4838-4841.
221. Saenz del Burgo L., Pedraz J.L., Orive G. Advanced nanovehicles for cancer management. Drug Discov. Today 2014, 19(10):1659-1670.
222. Sahoo S.K., Labhasetwar V. Nanotech approaches to drug delivery and imaging. Drug Discov. Today 2003, 8(24):1112-1120.
223. Sahoo S.K., Ma W., Labhasetwar V. Efficacy of transferrin-conjugated paclitaxel-loaded nanoparticles in a murine model of prostate cancer. Int. J. Cancer 2004, 112(2):335-340.
224. Sankhala K.K. A phase I pharmacokinetic (PK) study of MBP-426, a novel liposome encapsulated oxaliplatin. J. Clin. Oncol. 2009, 27:2535.
225. Sarris A.H., Hagemeister F., Romaguera J., Rodriguez M.A., McLaughlin P., Tsimberidou A.M., Medeiros L.J., Samuels B., Pate O., Oholendt M., Kantarjian H., Burge C., Cabanillas F. Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing phase II trial. Ann. Oncol. 2000, 11(1):69-72.
226. Sassoon, I., Blanc, V., 2013. Antibody-Drug Conjugate (ADC) Clinical Pipeline: A Review. In: Ducry, L. (Ed.), Humana Press, pp. 1-27.
227. Satouchi M., Okamoto I., Sakai H., Yamamoto N., Ichinose Y., Ohmatsu H., Nogami N., Takeda K., Mitsudomi T., Kasahara K., Negoro S. Efficacy and safety of weekly nab-paclitaxel plus carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer 2013, 81(1):97-101.
228. Scaltriti M., Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin. Cancer Res. 2006, 12(18):5268-5272.
229. Schrama D., Reisfeld R.A., Becker J.C. Antibody targeted drugs as cancer therapeutics. Nat. Rev. Drug Discov. 2006, 5(2):147-159.
230. Scott L., Yao J., Benson A., Thomas A., Falk S., Mena R., Picus J., Wright J., Mulcahy M., Ajani J., Evans T. A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma. Cancer Chemother. Pharmacol. 2009, 63(2):363-370.
231. Scott A.M., Wolchok J.D., Old L.J. Antibody therapy of cancer. Nat. Rev. Cancer 2012, 12(4):278-287.
232. Seetharamu N., Kim E., Hochster H., Martin F., Muggia F. Phase II study of liposomal cisplatin (SPI-77) in platinum-sensitive recurrences of ovarian cancer. Anticancer Res. 2010, 30(2):541-545.
233. Semple S.C., Leone R., Wang J., Leng E.C., Klimuk S.K., Eisenhardt M.L., Yuan Z., Edwards K., Maurer N., Hope M.J., Cullis P.R., Ahkong Q. Optimization and characterization of a sphingomyelin/cholesterol liposome formulation of vinorelbine with promising antitumor activity. J. Pharm. Sci. 2005, 94(5):1024-1038.
234. Senzer N., Nemunaitis J., Nemunaitis D., Bedell C., Edelman G., Barve M., Nunan R., Pirollo K.F., Rait A., Chang E.H. Phase I study of a systemically delivered p53 nanoparticle in advanced solid tumors. Mol. Ther. 2013, 21(5):1096-1103.
235. Seymour L.W., Ferry D.R., Anderson D., Hesslewood S., Julyan P.J., Poyner R., Doran J., Young A.M., Burtles S., Kerr D.J. Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J. Clin. Oncol. 2002, 20(6):1668-1676. Cancer Research Campaign Phase I/II Clinical Trials committee.
236. Seymour L.W., Ferry D.R., Kerr D.J., Rea D., Whitlock M., Poyner R., Boivin C., Hesslewood S., Twelves C., Blackie R., Schatzlein A., Jodrell D., Bissett D., Calvert H., Lind M., Robbins A., Burtles S., Duncan R., Cassidy J. Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. Int. J. Oncol. 2009, 34(6):1629-1636.
237. 3 integrin-overexpressing breast cancer cells. Drug Deliv. Transl. Res. 2015, 5(1):15-26.
238. Singal P.K., Iliskovic N. Doxorubicin-induced cardiomyopathy. N. Engl. J. Med. 1998, 339(13):900-905.
239. Slingerland M., Guchelaar H., Rosing H., Scheulen M.E., van Warmerdam L.J.C., Beijnen J.H., Gelderblom H. Bioequivalence of liposome-entrapped paclitaxel easy-to-use (LEP-ETU) formulation and paclitaxel in polyethoxylated castor oil: a randomized, two-period crossover study in patients with advanced cancer. Clin. Ther. 2013, 35(12):1946-1954.
240. Soepenberg O., de Jonge M.J.A., Sparreboom A., de Bruin P., Eskens F.A.L.M., de Heus G., Wanders J., Cheverton P., Ducharme M.P., Verweij J. Phase I and pharmacokinetic study of DE-310 in patients with advanced solid tumors. Clin. Cancer Res. 2005, 11(2):703-711.
241. Stathopoulos G.P., Boulikas T. Lipoplatin formulation review article. J. Drug Deliv. 2012, 2012:581363.
242. Stathopoulos G.P., Antoniou D., Dimitroulis J., Stathopoulos J., Marosis K., Michalopoulou P. Comparison of liposomal cisplatin versus cisplatin in non-squamous cell non-small-cell lung cancer. Cancer Chemother. Pharmacol. 2011, 68(4):945-950.
243. Stein G.S., Pardee A.B. Cell Cycle and Growth Control: Biomolecular Regulation and Cancer 2004, Springer.
244. Strumberg D., Schultheis B., Traugott U., Vank C., Santel A., Keil O., Giese K., Kaufmann J., Drevs J. Phase I clinical development of Atu027, a siRNA formulation targeting PKN3 in patients with advanced solid tumors. Int. J. Clin. Pharmacol. Ther. 2012, 50:76-78.
245. Suzuki R., Takizawa T., Kuwata Y., Mutoh M., Ishiguro N., Utoguchi N., Shinohara A., Eriguchi M., Yanagie H., Maruyama K. Effective anti-tumor activity of oxaliplatin encapsulated in transferrin-PEG-liposome. Int. J. Pharm. 2008, 346(1-2):143-150.
246. Tabernero J., Shapiro G.I., LoRusso P.M., Cervantes A., Schwartz G.K., Weiss G.J., Paz-Ares L., Cho D.C., Infante J.R., Alsina M., Gounder M.M., Falzone R., Harrop J., White A.C.S., Toudjarska I., Bumcrot D., Meyers R.E., Hinkle G., Svrzikapa N., Hutabarat R.M., Clausen V.A., Cehelsky J., Nochur S.V., Gamba-Vitalo C., Vaishnaw A.K., Sah D.W.Y., Gollob J.A., Burris H.A. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov. 2013, 3(4):406-417.
247. Tagami T., Ernsting M.J., Li S.D. Efficient tumor regression by a single and low dose treatment with a novel and enhanced formulation of thermosensitive liposomal doxorubicin. J. Control. Release 2011, 152(2):303-309.
248. Tagami T., Ernsting M.J., Li S.D. Optimization of a novel and improved thermosensitive liposome formulated with DPPC and a Brij surfactant using a robust in vitro system. J. Control. Release 2011, 154(3):290-297.
249. Taheri A., Dinarvand R., Atyabi F., Nouri F., Ahadi F., Ghahremani M.H., Ostad S.N., Borougeni A.T., Mansoori P. Targeted delivery of methotrexate to tumor cells using biotin functionalized methotrexate-human serum albumin conjugated nanoparticles. J. Biomed. Nanotechnol. 2011, 7(6):743-753.
250. Taheri A., Dinarvand R., Nouri F.S., Khorramizadeh M.R., Borougeni A.T., Mansoori P., Atyabi F. Use of biotin targeted methotrexate-human serum albumin conjugated nanoparticles to enhance methotrexate antitumor efficacy. Int. J. Nanomed. 2011, 6:1863-1874.
251. Taheri A., Dinarvand R., Atyabi F., Ghahremani M.H., Ostad S.N. Trastuzumab decorated methotrexate-human serum albumin conjugated nanoparticles for targeted delivery to HER2 positive tumor cells. Eur. J. Pharm. Sci. 2012, 47(2):331-340.
252. Tardi P., Choice E., Masin D., Redelmeier T., Bally M., Madden T.D. Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models. Cancer Res. 2000, 60(13):3389-3393.
253. Tari A.M., Gutierrez-Puente Y., Monaco G., Stephens C., Sun T., Rosenblum M., Belmont J., Arlinghaus R., Lopez-Berestein G. Liposome-incorporated Grb2 antisense oligodeoxynucleotide increases the survival of mice bearing bcr-abl-positive leukemia xenografts. Int. J. Oncol. 2007, 31(5):1243-1250.
254. Taylor R.M., Sillerud L.O. Paclitaxel-loaded iron platinum stealth immunomicelles are potent MRI imaging agents that prevent prostate cancer growth in a PSMA-dependent manner. Int. J. Nanomed. 2012, 7:4341-4352.
255. Temming K., Schiffelers R.M., Molema G., Kok R.J. RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature. Drug Resist. Updat. 2005, 8(6):381-402.
256. Tietze R., Zaloga J., Unterweger H., Lyer S., Friedrich R.P., Janko C., Pottler M., Durr S., Alexiou C. Magnetic nanoparticle-based drug delivery for cancer therapy. Biochem. Biophys. Res. Commun. 2015, 468:463-470.
257. Tolcher A.W., Rodrigueza W.V., Rasco D.W., Patnaik A., Papadopoulos K.P., Amaya A., Moore T.D., Gaylor S.K., Bisgaier C.L., Sooch M.P., Woolliscroft M.J., Messmann R.A. A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 2013, 73(2):363-371.
258. Tolcher A.W., Papadopoulos K.P., Patnaik A., Rasco D.W., Martinez D., Wood D.L., Fielman B., Sharma M., Janisch L.A., Brown B.D., Bhargava P., Ratain M.J. Safety and activity of DCR-MYC, a first-in-class Dicer-substrate small interfering RNA (DsiRNA) targeting MYC, in a phase I study in patients with advanced solid tumors in 2015 ASCO Annual Meeting. J. Clin. Oncol. 2015, 33:15.
259. Tong R., Cheng J. Anticancer polymeric nanomedicines. Polym. Rev. 2007, 47(3):345-381.
260. Torchilin V.P. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 2005, 4(2):145-160.
261. Torchilin V.P. Micellar nanocarriers: pharmaceutical perspectives. Pharm. Res. 2007, 24(1):1-16.
262. Torchilin V. Multifunctional and stimuli-sensitive pharmaceutical nanocarriers. Eur. J. Pharm. Biopharm. 2009, 71(3):431-444.
263. Tran T.H., Choi J.Y., Ramasamy T., Truong D.H., Nguyen C.N., Choi H., Yong C.S., Kim J.O. Hyaluronic acid-coated solid lipid nanoparticles for targeted delivery of vorinostat to CD44 overexpressing cancer cells. Carbohydr. Polym. 2014, 114:407-415.
264. Tseng C., Su W., Yen K., Yang K., Lin F. The use of biotinylated-EGF-modified gelatin nanoparticle carrier to enhance cisplatin accumulation in cancerous lungs via inhalation. Biomaterials 2009, 30(20):3476-3485.
265. Ueno T., Endo K., Hori K., Ozaki N., Tsuji A., Kondo S., Wakisaka N., Murono S., Kataoka K., Kato Y., Yoshizaki T. Assessment of antitumor activity and acute peripheral neuropathy of 1,2-diaminocyclohexane platinum (II)-incorporating micelles (NC-4016). Int. J. Nanomed. 2014, 9:3005-3012.
266. Ugwu S., Zhang A., Parmar M., Miller B., Sardone T., Peikov V., Ahmad I. Preparation, characterization, and stability of liposome-based formulations of mitoxantrone. Drug Dev. Ind. Pharm. 2005, 31(2):223-229.
267. Valle J.W., Armstrong A., Newman C., Alakhov V., Pietrzynski G., Brewer J., Campbell S., Corrie P., Rowinsky E.K., Ranson M. A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction. Invest. New Drugs 2011, 29(5):1029-1037.
268. van Broekhoven C.L., Parish C.R., Demangel C., Britton W.J., Altin J.G. Targeting dendritic cells with antigen-containing liposomes: a highly effective procedure for induction of antitumor immunity and for tumor immunotherapy. Cancer Res. 2004, 64(12):4357-4365.
269. Vanneman M., Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat. Rev. Cancer 2012, 12(4):237-251.
270. Vasir J.K., Labhasetwar V. Biodegradable nanoparticles for cytosolic delivery of therapeutics. Adv. Drug Deliv. Rev. 2007, 59(8):718-728.
271. Vecchione L., Jacobs B., Normanno N., Ciardiello F., Tejpar S. EGFR-targeted therapy. Exp. Cell Res. 2011, 317(19):2765-2771.
272. Veltkamp S.A., Witteveen E.O., Capriati A., Crea A., Animati F., Voogel-Fuchs M., van den Heuvel I.J.G.M., Beijnen J.H., Voest E.E., Schellens J.H.M. Clinical and pharmacologic study of the novel prodrug delimotecan (MEN 4901/T-0128) in patients with solid tumors. Clin. Cancer Res. 2008, 14(22):7535-7544.
273. Venkatakrishnan K., Liu Y., Noe D., Mertz J., Bargfrede M., Marbury T., Farbakhsh K., Oliva C., Milton A. Pharmacokinetics and pharmacodynamics of liposomal mifamurtide in adult volunteers with mild or moderate hepatic impairment. Br. J. Clin. Pharmacol. 2014, 77(6):998-1010.
274. Verma S., Miles D., Gianni L., Krop I.E., Welslau M., Baselga J., Pegram M., Oh D., Diéras V., Guardino E., Fang L., Lu M.W., Olsen S., Blackwell K. Trastuzumab emtansine for HER2-positive advanced breast cancer. N. Engl. J. Med. 2012, 367(19):1783-1791.
275. Verschraegen C.F., Gilbert B.E., Huaringa A.J., Newman R., Harris N., Leyva F.J., Keus L., Campbell K., Nelson-Taylor T., Knight V. Feasibility, phase I, and pharmacological study of aerosolized liposomal 9-nitro-20(S)-camptothecin in patients with advanced malignancies in the lungs. Ann. NY Acad. Sci. 2000, 922:352-354.
276. Visser C.C., Stevanovic S., Heleen Voorwinden L., Gaillard P.J., Crommelin D.J., Danhof M., De Boer A.G. Validation of the transferrin receptor for drug targeting to brain capillary endothelial cells in vitro. J. Drug Target. 2004, 12(3):145-150.
277. Von Hoff D.D., Ervin T., Arena F.P., Chiorean E.G., Infante J., Moore M., Seay T., Tjulandin S.A., Ma W.W., Saleh M.N., Harris M., Reni M., Dowden S., Laheru D., Bahary N., Ramanathan R.K., Tabernero J., Hidalgo M., Goldstein D., Van Cutsem E., Wei X., Iglesias J., Renschler M.F. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. 2013, 369(18):1691-1703.
278. Wadleigh M., Richardson P.G., Zahrieh D., Lee S.J., Cutler C., Ho V., Alyea E.P., Antin J.H., Stone R.M., Soiffer R.J., DeAngelo D.J. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood 2003, 102(5):1578-1582.
279. Wang X., Wang Y., Chen Z.G., Shin D.M. Advances of cancer therapy by nanotechnology. Cancer Res. Treat. 2009, 41(1):1-11.
280. Wang W., Xi M., Duan X., Wang Y., Kong F. Delivery of baicalein and paclitaxel using self-assembled nanoparticles: synergistic antitumor effect in vitro and in vivo. Int. J. Nanomed. 2015, 10:3737-3750.
281. Weiner L.M., Dhodapkar M.V., Ferrone S. Monoclonal antibodies for cancer immunotherapy. Lancet 2009, 373(9668):1033-1040.
282. Weiss G.J., Chao J., Neidhart J.D., Ramanathan R.K., Bassett D., Neidhart J.A., Choi C.H., Chow W., Chung V., Forman S.J., Garmey E., Hwang J., Kalinoski D.L., Koczywas M., Longmate J., Melton R.J., Morgan R., Oliver J., Peterkin J.J., Ryan J.L., Schluep T., Synold T.W., Twardowski P., Davis M.E., Yen Y. First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies. Invest. New Drugs 2013, 31(4):986-1000.
283. Werner M.E., Karve S., Sukumar R., Cummings N.D., Copp J.A., Chen R.C., Zhang T., Wang A.Z. Folate-targeted nanoparticle delivery of chemo- and radiotherapeutics for the treatment of ovarian cancer peritoneal metastasis. Biomaterials 2011, 32(33):8548-8554.
284. National Cancer Institute at the National Institutes of Health, 2015. What is Cancer? Available from: . http://www.cancer.gov/about-cancer/what-is-cancer.
285. Wicki A., Witzigmann D., Balasubramanian V., Huwyler J. Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications. J. Control. Release 2015, 200:138-157.
286. Winer I., Wang S., Lee Y.E., Fan W., Gong Y., Burgos-Ojeda D., Spahlinger G., Kopelman R., Buckanovich R.J. F3-targeted cisplatin-hydrogel nanoparticles as an effective therapeutic that targets both murine and human ovarian tumor endothelial cells in vivo. Cancer Res. 2010, 70(21):8674-8683.
287. Wittgen B.P., Kunst P.W., van der Born K., van Wijk A.W., Perkins W., Pilkiewicz F.G., Perez-Soler R., Nicholson S., Peters G.J., Postmus P.E. Phase I study of aerosolized SLIT cisplatin in the treatment of patients with carcinoma of the lung. Clin. Cancer Res. 2007, 13(8):2414-2421.
288. Witton C.J., Reeves J.R., Going J.J., Cooke T.G., Bartlett J.M. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J. Pathol. 2003, 200(3):290-297.
289. Wu H., Ramanathan R.K., Zamboni B.A., Strychor S., Ramalingam S., Edwards R.P., Friedland D.M., Stoller R.G., Belani C.P., Maruca L.J., Bang Y., Zamboni W.C. Population pharmacokinetics of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies. J. Clin. Pharmacol. 2011, 52:180-194.
290. Xia W., Hilgenbrink A.R., Matteson E.L., Lockwood M.B., Cheng J., Low P.S. A functional folate receptor is induced during macrophage activation and can be used to target drugs to activated macrophages. Blood 2008, 113(2):438-446.
291. Xie X., Xia W., Li Z., Kuo H., Liu Y., Li Z., Ding Q., Zhang S., Spohn B., Yang Y., Wei Y., Lang J., Evans D.B., Chiao P.J., Abbruzzese J.L., Hung M. Targeted expression of BikDD eradicates pancreatic tumors in noninvasive imaging models. Cancer Cell 2007, 12(1):52-65.
292. Xin H., Jiang X., Gu J., Sha X., Chen L., Law K., Chen Y., Wang X., Jiang Y., Fang X. Angiopep-conjugated poly(ethylene glycol)-co-poly(?-caprolactone) nanoparticles as dual-targeting drug delivery system for brain glioma. Biomaterials 2011, 32(18):4293-4305.
293. Xu L., Tang W.H., Huang C.C., Alexander W., Xiang L.M., Pirollo K.F., Rait A., Chang E.H. Systemic p53 gene therapy of cancer with immunolipoplexes targeted by anti-transferrin receptor scFv. Mol. Med. 2001, 7(10):723-734.
294. Xu S., Olenyuk B.Z., Okamoto C.T., Hamm-Alvarez S.F. Targeting receptor-mediated endocytotic pathways with nanoparticles: rationale and advances. Adv. Drug Deliv. Rev. 2013, 65(1):121-138.
295. Xu X., Wang L., Xu H.Q., Huang X.E., Qian Y.D., Xiang J. Clinical comparison between paclitaxel liposome (Lipusu®) and paclitaxel for treatment of patients with metastatic gastric cancer. Asian Pac. J. Cancer Prev. 2013, 14(4):2591-2594.
296. Yang S., Lin C., Lin Z., Tseng Y., Hong R. A phase I and pharmacokinetic study of liposomal vinorelbine in patients with advanced solid tumor. Invest. New Drugs 2012, 30(1):282-289.
297. Yin X., Wu L., Fu H., Huang M., Wang K., Zhou F., Yu X., Wang K. Inhibitory effect of humanized anti-VEGFR-2 ScFv-As2O3-stealth nanoparticles conjugate on growth of human hepatocellular carcinoma: in vitro and in vivo studies. Asian Pac. J. Trop. Med. 2014, 7(5):337-343.
298. Younes A., Bartlett N.L., Leonard J.P., Kennedy D.A., Lynch C.M., Sievers E.L., Forero-Torres A. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N. Engl. J. Med. 2010, 363(19):1812-1821.
299. Younes A., Gopal A.K., Smith S.E., Ansell S.M., Rosenblatt J.D., Savage K.J., Ramchandren R., Bartlett N.L., Cheson B.D., de Vos S., Forero-Torres A., Moskowitz C.H., Connors J.M., Engert A., Larsen E.K., Kennedy D.A., Sievers E.L., Chen R. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J. Clin. Oncol. 2012, 30(18):2183-2189.
300. Yu B., Tai H.C., Xue W., Lee L.J., Lee R.J. Receptor-targeted nanocarriers for therapeutic delivery to cancer. Mol. Membr. Biol. 2010, 27(7):286-298.
301. Yurkovetskiy A.V., Fram R.J. XMT-1001, a novel polymeric camptothecin pro-drug in clinical development for patients with advanced cancer. Adv. Drug Deliv. Rev. 2009, 61(13):1193-1202.
302. Yusuf-Makagiansar H., Siahaan T. Binding and internalization of an LFA-1-derived cyclic peptide by ICAM receptors on activated lymphocyte: a potential ligand for drug targeting to ICAM-1-expressing cells. Pharm. Res. 2001, 18(3):329-335.
303. Zhao X., Li H., Lee R.J. Targeted drug delivery via folate receptors. Expert Opin. Drug Deliv. 2008, 5(3):309-319.
304. Zhou Q., Sun X., Zeng L., Liu J., Zhang Z. A randomized multicenter phase II clinical trial of mitoxantrone-loaded nanoparticles in the treatment of 108 patients with unresected hepatocellular carcinoma. Nanomedicine 2009, 5(4):419-423.
305. Zhou J., Shum K.T., Burnett J.C., Rossi J.J. Nanoparticle-based delivery of RNAi therapeutics: progress and challenges. Pharmaceuticals 2013, 6(1):85-107.
306. Zhu L., Torchilin V.P. Stimulus-responsive nanopreparations for tumor targeting. Integr. Biol. 2013, 5(1):96-107.